Allen Gong, an analyst from J.P. Morgan, has initiated a new Buy rating on Alphatec Holdings (ATEC).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Allen Gong’s rating is based on Alphatec Holdings’ significant transformation since 2018, which has positioned it as a leading player in the spine market with robust double-digit growth. The company’s flagship prone transpsoas (PTP) approach to lumbar interbody fusion (LIF) and a suite of enabling technologies have driven this growth, allowing Alphatec to capture market share from traditional methods and capitalize on competitor disruptions.
Moreover, Alphatec’s strategic acquisitions have enhanced its technology offerings, covering the entire continuum of care, which is a trend seen across orthopedics. This has contributed to Alphatec’s differentiated growth profile. With a reasonable valuation and untapped growth opportunities, particularly in international markets, Gong is optimistic about Alphatec’s potential for sustained above-market growth and profitability heading into 2026.
In another report released on October 16, Wells Fargo also maintained a Buy rating on the stock with a $16.00 price target.
Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ATEC in relation to earlier this year.